$SLS

AI 分析

生成於 May 13, 2026

AI Score
28/ 100
Sell$SLS

SELLAS Life Sciences Group

$SLSNASDAQHealthcareSmall-Cap

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies, with lead asset galinpepimut-S (GPS) for hematologic cancers.

Market Cap
$0.08B
Revenue (TTM)
$0.01B
N/A
Net Income (TTM)
-$0.03B
N/A
EPS (TTM)
-$1.20
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$1-$5
Beta
1.95
Dimension Scores
Fundamental
15
Technical
32
Sentiment
38
Risk / Reward
22
Momentum
35
FundTechSentRiskMome
Financial Health
Profitability
20weak
Growth
38weak
Liquidity
30strong
Solvency
17moderate
Efficiency
13moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $SLS

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。